MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has opened a €290 million biosafety testing facility in Rockville, Maryland. The new 23,000-square-meter facility is designed to meet growing global demand for biosafety testing and analytical
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has announced the launch of its Mobius ADC Reactor. This single-use reactor is tailored for the production of antibody-drug conjugates (ADCs), a class of therapeutics known for
MilliporeSigma has announced a €62 million investment in a new quality control building at its Darmstadt headquarters. Scheduled for completion by mid-2025, the nearly 10,000 square meter facility will consolidate approximately 135 employees from various departments into a collaborative, state-of-the-art
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has announced its plans to acquire Mirus Bio, a life science company based in Madison, Wisconsin, USA. The deal, valued at $600 million, is part of MilliporeSigma’s
MilliporeSigma, the North American life sciences business and part of Merck KGaA, is making a significant investment in South Korea. The company is investing €300 million ($326 million) into a new production center in Daejeon, where it expects to create
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
